BDSI Share Price

Open 1.70 Change Price %
High 1.80 1 Day -0.05 -2.86
Low 1.70 1 Week -0.05 -2.86
Close 1.70 1 Month -0.25 -12.82
Volume 330357 1 Year -3.48 -67.18
52 Week High 5.48
52 Week Low 0.00
BDSI Important Levels
Resistance 2 1.79
Resistance 1 1.75
Pivot 1.73
Support 1 1.65
Support 2 1.61
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 20.45 7.29%
MU 20.45 7.29%
MU 20.45 7.29%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
ANTH 2.03 38.10%
EMKR 8.45 31.01%
MBLX 0.32 28.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
HTCO 8.00 23.08%
ATEA 1.95 21.88%
ATEA 1.95 21.88%
More..
NASDAQ USA Top Losers Stocks
DSTI 0.00 -100.00%
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

BioDelivery Sciences International, Inc. (NASDAQ: BDSI)

BDSI Technical Analysis 5
As on 7th Dec 2016 BDSI Share Price closed @ 1.70 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.80 & Strong Sell for SHORT-TERM with Stoploss of 2.19 we also expect STOCK to react on Following IMPORTANT LEVELS.
BDSI Target for December
1st Target up-side 2.19
2nd Target up-side 2.53
3rd Target up-side 2.88
1st Target down-side 1.21
2nd Target down-side 0.87
3rd Target down-side 0.52
BDSI Other Details
Segment EQ
Market Capital 145113200.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.bdsi.com
BDSI Address
BDSI
801 Corporate Center Drive
Suite 210
Raleigh, NC 27607
United States
Phone: 919-582-9050
Fax: 919-582-9051
Interactive Technical Analysis Chart BioDelivery Sciences International, Inc. ( BDSI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on BioDelivery Sciences International, Inc.
BDSI Business Profile
BioDelivery Sciences International, Inc. (BDSI), incorporated on January 6, 199, is a specialty pharmaceutical company. BDSI is developing and commercializing, either on its own or in partnerships with third parties, applications of therapeutics to address medical needs. The Company has developed and is continuing to develop pharmaceutical products aimed principally in the areas of pain management and oncology supportive care. In formulating the Company's products and product candidates, BDSI utilizes the BioErodible MucoAdhesive (BEMA) drugs delivery technology, a small, erodible polymer film for application to the buccal mucosa. The Company's the United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its pipeline of product candidates, utilize its BEMA technology. ONSOLIS is indicated for the treatment of pain in opioid tolerant patients with cancer. As of December 31, 2011, BDSI was developing BEMA Buprenorphine, a treatment for moderate to severe chronic pain. On September 28, 2011, the Company announced the preliminary findings of its randomized, placebo-controlled, Phase III clinical study of BEMA Buprenorphine for the treatment of moderate to severe chronic pain in a mixed opioid naive and opioid experienced population. BEMA Buprenorphine/Naloxone is its product candidate. The Company is developing a formulation of BEMA Buprenorphine for the treatment of opioid dependence. As of December 31, 2011, the Company owned the BEMA drug delivery technology. BEMA Granisetron product candidate utilizes the BEMA technology to deliver the 5-HT3 receptor antagonist Granisetron.